The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 15, 2005
Filed:
Jul. 30, 2002
Yehuda Mazur, Tel Aviv, IL;
Gad Lavie, Rehovot, IL;
Yehuda Mazur, Tel Aviv, IL;
Gad Lavie, Rehovot, IL;
Yeda Research and Development Co. Ltd., Rehovot, IL;
New York University, New York, NY (US);
Abstract
Hypericin, helianthrone and derivatives thereof of general formula (I)wherein the dotted line between positions 11 and 12 represent an optional C11-C12 bond; R is independently selected from the group consisting of hydroxy, C-Calkoxy, NH—C-Calkyl, and NH-hydroxy(C-C)alkyl; R' is independently selected from the group consisting of hydroxy and C-Calkoxy; R″ is independently selected from the group consisting of hydrogen, hydroxy, C-Calkoxy, NH—C-Calkyl, and NH-hydroxy(C-C)alkyl; and R, R, R, R, Rand Rare independently selected from the group consisting of hydrogen, hydroxy, chloro, bromo, C-Calkyl, C-Calkoxy, and C-Calkoxycarbonyl, provided that R″ is not hydrogen when there is a C11-C12 bond, are useful as inhibitors of angiogenesis and can be used to prevent formation of metastases and restenosis and for the treatment of angiogenesis-associated ophthalmologic disorders. In addition, the helianthrones of formula (I) can be used for the treatment of tumors in the absence of light irradiation. New compounds include those of formula I which are other than hypericin and known hypericin derivatives and there is either a C11-C12 bond or at least one R″ is other than hydrogen.